Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about blood: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| 38a05d38_25e_spec | describes | wiki | 0.90 |
| Cryptic Hdgfl2 | expressed_in | biomarker | 0.90 |
| biomarkers-blood-based-biomarkers-neurodegeneration | describes | wiki | 0.90 |
| biomarkers-blood-biomarkers-atypical-parkinsonism | describes | wiki | 0.90 |
| biomarkers-blood-microbial-signatures-parkinson | describes | wiki | 0.90 |
| biomarkers-blood-ptau217-onset-timing-clock | describes | wiki | 0.90 |
| biomarkers-blood-ptau-systemic-amyloidosis | describes | wiki | 0.90 |
| Cryptic HDGFL2 | expressed_in | biomarker | 0.88 |
| HSPA1A | expressed_in | gene | 0.64 |
| HSPA1B | expressed_in | gene | 0.64 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 1 hypotheses Top: 0.460
neurodegeneration | 2026-04-26 | 1 hypotheses Top: 0.600
neurodegeneration | 2026-04-26 | 1 hypotheses Top: 0.615
neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.750
neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - ALOX15 overexpression in healthy astrocytes should be protectiv | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $130,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Progranulin Replacement Therapy for FTD — Vector Development and Valid | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies [PMID:40447280] | Russell CD, Goeldner-Thompson S, Smith E | J Infect Dis | 2025 | 1 |
| An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766] | Huang Q, Chan KY, Wu J, Botticello-Romer | Science | 2024 | 1 |
| Targeting the transferrin receptor to transport antisense oligonucleotides acros [PMID:39141703] | Barker SJ, Thayer MB, Kim C, Tatarakis D | Sci Transl Med | 2024 | 1 |
| Blood-brain barrier transport using a high affinity, brain-selective VNAR antibo [PMID:33241587] | Stocki P, Szary J, Rasmussen CLM, Demydc | FASEB J | 2021 | 1 |
| Transferrin receptor 1 in cancer: a new sight for cancer therapy. [PMID:30034931] | Shen Y, Li X, Dong D, Zhang B, Xue Y, Sh | American journal of cancer res | 2018 | 1 |
| Cadmium exposure is associated with impaired ovarian function: Potential role of [PMID:41548307] | ["Li J", "Wang Y", "Huang Y", "Li N", "Z | Journal of hazardous materials | 2026 | 0 |
| A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456] | Yesiltepe M, Metkar S, Yin T, Chakrabort | The Journal of biological chem | 2026 | 0 |
| Early hypoxia-induced secretome remodeling reveals adaptive mechanisms and bioma [PMID:41699623] | Wu Q, Jiang Y, Peng L, Dang Y, You C, Li | Molecular brain | 2026 | 0 |
| MITF programs macrophage iron homeostasis to drive gut-liver inflammatory axis i [PMID:41832955] | Han D, Han L, Kang L, Liu J, Zhang N, Tu | Cell reports | 2026 | 0 |
| Ferrostatin-1 alleviates experimental cerebral malaria by regulating immune cell [PMID:41422632] | Yao S, Zhou X, Liao T, Yao C, Sun M, Gou | International journal for para | 2025 | 0 |
| Dietary Iron Deficiency in Adult Mice Increases Brain Uptake of High-Affinity, A [PMID:41299828] | Kostrikov S, Johnsen KB, Burkhart A, Hel | Journal of neurochemistry | 2025 | 0 |
| A covalent peptide-based lysosome-targeting protein degradation platform for can [PMID:39910101] | Xiao Y, He Z, Li W, Chen D, Niu X, Yang | Nature communications | 2025 | 0 |
| Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis. [PMID:38743190] | ["Hu K", "Jiang P", "Hu J", "Song B", "H | Journal of bioenergetics and b | 2024 | 0 |
| P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667] | Zhang D, Zhang W, Ming C, Gao X, Yuan H, | Neuron | 2024 | 0 |
| The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117] | Balusu S, De Strooper B | Acta neuropathologica | 2024 | 0 |
| Ferroptosis promotes valproate-induced liver steatosis in vitro and in vivo. [PMID:39147356] | ["Yan X", "Ma L", "Chen X", "Ren J", "Zh | Food and chemical toxicology : | 2024 | 0 |
| TfR-conjugated nanoparticles achieve 50-fold increase in brain delivery vs free [PMID:synthetic_13] | Unknown | ACS Nano | 2023 | 0 |
| Specialized pro-resolving mediators reduce brain inflammation and amyloid pathol [PMID:synthetic_9] | Unknown | Nature Med | 2023 | 0 |
| TfR saturation limits uptake of targeting ligands at physiological transferrin c [PMID:synthetic_15] | Unknown | Mol Pharm | 2022 | 0 |
| Resolvin D1 promotes microglial phagocytosis and suppresses inflammatory cytokin [PMID:synthetic_11] | Unknown | J Neuroinflammation | 2021 | 0 |
Multi-agent debates referencing this entity
active · Rounds: 4 · Score: 1.00 · 2026-04-26
active · Rounds: 4 · Score: 1.00 · 2026-04-26
active · Rounds: 4 · Score: 1.00 · 2026-04-26
closed · Rounds: 4 · Score: 0.78 · 2026-04-26
active · Rounds: 7 · Score: 0.00 · 2026-04-26
closed · Rounds: 4 · Score: 0.76 · 2026-04-23
closed · Rounds: 4 · Score: 0.82 · 2026-04-22
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
closed · Rounds: 4 · Score: 0.50 · 2026-04-18
closed · Rounds: 4 · Score: 0.50 · 2026-04-18
Hypotheses and analyses mentioning blood in their description or question text
Score: 0.533 · neurodegeneration · 2026-04-02
## Mechanistic Overview Blood-Brain Barrier SPM Shuttle System starts from the claim that modulating TFRC within the dis
Score: 0.520 · biomarkers · 2026-04-22
## Mechanistic Overview Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming starts from the claim th
Score: 0.513 · neuroinflammation · 2026-04-14
## Mechanistic Overview GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltr
Score: 0.499 · neuroscience · 2026-04-21
## Mechanistic Overview TREM2-Mediated Microglial Dysfunction Drives Tau-Induced Blood-Brain Barrier Breakdown starts fr
Score: 0.430 · neurodegeneration · 2026-04-21
## Mechanistic Overview Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult starts from the claim tha
Score: 0.406 · molecular biology · 2026-04-21
## Mechanistic Overview Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Transferrin Recepto
Score: 0.220 · metabolomics · 2026-04-25
Blood-Brain Barrier Metabolite Transporter Enhancement for Diagnostic and Therapeutic Dual Benefit